# Oscar Lorenzo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/246558/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 76 papers | 5,839 citations | 81743 39 h-index | 76769 74 g-index |
| 79 all docs | 79 docs citations | 79 times ranked | 7950 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Inflammation and angiotensin II. International Journal of Biochemistry and Cell Biology, 2003, 35, 881-900. | 1.2 | 603 |
| 2 | Proinflammatory actions of angiotensins. Current Opinion in Nephrology and Hypertension, 2001, 10, 321-329. | 1.0 | 361 |
| 3 | Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney International, 2002, 62, S12-S22. | 2.6 | 338 |
| 4 | Angiotensin II Activates Nuclear Transcription Factor ÎºB Through AT<sub>1</sub>and AT<sub>2</sub>in Vascular Smooth Muscle Cells. Circulation Research, 2000, 86, 1266-1272. | 2.0 | 308 |
| 5 | Role of the Renin-Angiotensin System in Vascular Diseases. Hypertension, 2001, 38, 1382-1387. | 1.3 | 268 |
| 6 | Connective Tissue Growth Factor Is a Mediator of Angiotensin IIâ€“Induced Fibrosis. Circulation, 2003, 108, 1499-1505. | 1.6 | 248 |
| 7 | Phosphatidylinositol-5-Phosphate Activation and Conserved Substrate Specificity of the Myotubularin Phosphatidylinositol 3-Phosphatases. Current Biology, 2003, 13, 504-509. | 1.8 | 218 |
| 8 | Angiotensin II, via AT1 and AT2 Receptors and NF-ÂB Pathway, Regulates the Inflammatory Response in Unilateral Ureteral Obstruction. Journal of the American Society of Nephrology: JASN, 2004, 15, 1514-1529. | 3.0 | 218 |
| 9 | Activation of the Endosome-Associated Ubiquitin Isopeptidase AMSH by STAM, a Component of the Multivesicular Body-Sorting Machinery. Current Biology, 2006, 16, 160-165. | 1.8 | 190 |
| 10 | Systemic Infusion of Angiotensin II into Normal Rats Activates Nuclear Factor-ÎºB and AP-1 in the Kidney. American Journal of Pathology, 2001, 158, 1743-1756. | 1.9 | 170 |
| 11 | Diagnostic approaches for diabetic cardiomyopathy. Cardiovascular Diabetology, 2017, 16, 28. | 2.7 | 165 |
| 12 | Potential Role of Nuclear Factor<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold">Îº</mml:mi></mml:math>B in Diabetic Cardiomyopathy. Mediators of Inflammation, 2011, 2011, 1-9. | 1.4 | 139 |
| 13 | Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovascular Diabetology, 2017, 16, 44. | 2.7 | 136 |
| 14 | Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opinion on Investigational Drugs, 2018, 27, 917-930. | 1.9 | 133 |
| 15 | Angiotensin III increases MCP-1 and activates NF-ÐºB and AP-1 in cultured mesangial and mononuclear cells. Kidney International, 2000, 57, 2285-2298. | 2.6 | 111 |
| 16 | Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. Cardiovascular Diabetology, 2019, 18, 140. | 2.7 | 101 |
| 17 | Angiotensin IV Activates the Nuclear Transcription Factor-ÎºB and Related Proinflammatory Genes in Vascular Smooth Muscle Cells. Circulation Research, 2005, 96, 965-973. | 2.0 | 97 |
| 18 | Angiotensin II Increases Connective Tissue Growth Factor in the Kidney. American Journal of Pathology, 2003, 163, 1937-1947. | 1.9 | 96 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H2109-H2119. | 1.5 | 95 |
| 20 | IL-1Î² Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Frontiers in Pharmacology, 2017, 8, 363. | 1.6 | 92 |
| 21 | The Myotubularin Family of Lipid Phosphatases. Traffic, 2005, 6, 1063-1069. | 1.3 | 90 |
| 22 | Differential redox regulation within the PTP superfamily. Cellular Signalling, 2007, 19, 1521-1530. | 1.7 | 89 |
| 23 | Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosomerelated functions. Journal of Cell Science, 2006, 119, 2953-2959. | 1.2 | 85 |
| 24 | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?. Frontiers in Pharmacology, 2020, 11, 1161. | 1.6 | 80 |
| 25 | Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation. International Journal of Endocrinology, 2014, 2014, 1-10. | 0.6 | 79 |
| 26 | Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. PLoS ONE, 2013, 8, e78330. | 1.1 | 76 |
| 27 | Angiotensin II activates nuclear transcription factorâ€ºB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrology Dialysis Transplantation, 2001, 16, 27-33. | 0.4 | 74 |
| 28 | Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific Reports, 2020, 10, 5386. | 1.6 | 69 |
| 29 | Analysis of phosphoinositide binding domain properties within the myotubularin-related protein MTMR3. Journal of Cell Science, 2005, 118, 2005-2012. | 1.2 | 67 |
| 30 | Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2014, 113, 434-440. | 0.7 | 66 |
| 31 | Alteration of Energy Substrates and ROS Production in Diabetic Cardiomyopathy. Mediators of Inflammation, 2013, 2013, 1-11. | 1.4 | 60 |
| 32 | Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovascular Diabetology, 2013, 12, 172. | 2.7 | 59 |
| 33 | Updating Experimental Models of Diabetic Cardiomyopathy. Journal of Diabetes Research, 2015, 2015, 1-15. | 1.0 | 58 |
| 34 | Angiotensin II Increases Parathyroid Hormone-Related Protein (PTHrP) and the Type 1 PTH/PTHrP Receptor in the Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 1595-1607. | 3.0 | 53 |
| 35 | Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 207-222. | 1.1 | 52 |
| 36 | Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. Survey of Ophthalmology, 2009, 54, 339-348. | 1.7 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Targeting metabolic disturbance in the diabetic heart. Cardiovascular Diabetology, 2015, 14, 17. | 2.7 | 44 |
| 38 | Coexistence of Low Vitamin D and High Fibroblast Growth Factor-23 Plasma Levels Predicts an Adverse Outcome in Patients with Coronary Artery Disease. PLoS ONE, 2014, 9, e95402. | 1.1 | 44 |
| 39 | Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney International, 1998, 54, S41-S45. | 2.6 | 41 |
| 40 | Proteomic Strategies in the Search of New Biomarkers in Atherothrombosis. Journal of the American College of Cardiology, 2010, 55, 2009-2016. | 1.2 | 41 |
| 41 | ACE inhibitors and AT1 receptor antagonistsâ€"beyond the haemodynamic effect. Nephrology Dialysis Transplantation, 2000, 15, 561-565. | 0.4 | 39 |
| 42 | Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking. Cardiovascular Diabetology, 2018, 17, 12. | 2.7 | 37 |
| 43 | Angiotensin III Activates Nuclear Transcription Factor-ÎºB in Cultured Mesangial Cells Mainly via AT2 Receptors. Journal of the American Society of Nephrology: JASN, 2002, 13, 1162-1171. | 3.0 | 34 |
| 44 | Proteome changes in the myocardium of experimental chronic diabetes and hypertension. Journal of Proteomics, 2012, 75, 1816-1829. | 1.2 | 33 |
| 45 | Circulating fibroblast growth factorâ€23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. Diabetes/Metabolism Research and Reviews, 2016, 32, 685-693. | 1.7 | 29 |
| 46 | Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals. Hepatology, 2022, 75, 550-566. | 3.6 | 25 |
| 47 | Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. International Journal of Molecular Sciences, 2020, 21, 6471. | 1.8 | 21 |
| 48 | Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS ONE, 2017, 12, e0169826. | 1.1 | 21 |
| 49 | Customized Dietary Intervention Avoids Unintentional Weight Loss and Modulates Circulating miRNAs Footprint in Huntington's Disease. Molecular Nutrition and Food Research, 2018, 62, e1800619. | 1.5 | 17 |
| 50 | Linking LOXL2 to Cardiac Interstitial Fibrosis. International Journal of Molecular Sciences, 2020, 21, 5913. | 1.8 | 17 |
| 51 | Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 293-303. | 1.8 | 15 |
| 52 | The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. Cardiology, 2015, 132, 1-8. | 0.6 | 15 |
| 53 | Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. Journal of Cardiology, 2015, 66, 22-27. | 0.8 | 15 |
| 54 | Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1105. | 1.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. PLoS ONE, 2015, 10, e0126741. | 1.1 | 15 |
| 56 | MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. Journal of Clinical Medicine, 2021, 10, 1137. | 1.0 | 14 |
| 57 | Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. Journal of Bone and Mineral Metabolism, 2016, 34, 587-598. | 1.3 | 13 |
| 58 | Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. PLoS ONE, 2016, 11, e0152816. | 1.1 | 12 |
| 59 | Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. Expert Review of Proteomics, 2016, 13, 857-871. | 1.3 | 11 |
| 60 | Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease. Journal of Nutrition, Health and Aging, 2016, 20, 659-664. | 1.5 | 11 |
| 61 | Lipid Biomarkers as Predictors of Diastolic Dysfunction in Diabetes with Poor Glycemic Control. International Journal of Molecular Sciences, 2020, 21, 5079. | 1.8 | 10 |
| 62 | Parathormone levels add prognostic ability to Nâ€terminal proâ€brain natriuretic peptide in stable coronary patients. ESC Heart Failure, 2021, 8, 2713-2722. | 1.4 | 10 |
| 63 | Addition of Probiotics to Anti-Obesity Therapy by Percutaneous Electrical Stimulation of Dermatome T6. A Pilot Study. International Journal of Environmental Research and Public Health, 2020, 17, 7239. | 1.2 | 8 |
| 64 | Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial. BMJ Open, 2016, 6, e011287. | 0.8 | 7 |
| 65 | Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3037. | 1.0 | 7 |
| 66 | PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2021, 14, 238-245. | 1.1 | 6 |
| 67 | The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 25-30. | 1.5 | 5 |
| 68 | Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 762-767. | 1.1 | 3 |
| 69 | Activation of bombesin receptor Subtype-3 by [D-Tyr 6 ,Î²-Ala 11 ,Phe 13 ,Nle 14 ]bombesin 6-14 increased glucose uptake and lipogenesis in human and rat adipocytes. Molecular and Cellular Endocrinology, 2018, 474, 10-19. | 1.6 | 3 |
| 70 | N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients. Journal of Clinical Medicine, 2021, 10, 4042. | 1.0 | 2 |
| 71 | Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. Texas Heart Institute Journal, 2017, 44, 239-244. | 0.1 | 2 |
| 72 | Impacto de la funciÃ³n renal en el valor pronÃ³stico del metabolismo mineral en pacientes con cardiopatÃa isquÃ©mica crÃ³nica. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2022, 34, 1-9. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. Journal of Clinical Medicine, 2022, 11, 4153. | 1.0 | 1 |
| 74 | ProteÃ³mica cardiovascular: una nueva tecnologÃa para resolver viejos problemas. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2011, 23, 183-185. | 0.4 | 0 |
| 75 | GLP-1 Isoforms for Diabetes-associated Cardiovascular Pathologies. Journal of Hypertension: Open Access, 2013, 02, . | 0.2 | 0 |
| 76 | Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, , . | 0.1 | 0 |